Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01974804|
Recruitment Status : Active, not recruiting
First Posted : November 3, 2013
Last Update Posted : March 13, 2020
|Condition or disease||Intervention/treatment|
|Brain Cancer||Procedure: MRI|
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Official Title:||Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis|
|Study Start Date :||October 2013|
|Estimated Primary Completion Date :||October 2021|
|Estimated Study Completion Date :||October 2021|
Pts having an MRI
Patients will undergo a 20 minute pretreatment MRI scan and a 30 minute post treatment MRI scan with contrast agent administration. Ten patients with brain metastasis will be recruited in the study. All the patients will be undergoing SRS (Stereotactic Radiosurgery). Patients will have 1 pretreatment evaluation and 2 post treatment evaluations [1-72 hours post treatment and 8 weeks (+/- 2 weeks) post treatment] for early response. Patients are to be administered contrast prior to obtaining MRI scans. These research scans are estimated to take 20 minutes of scan time (+/- 10 minutes), which includes patient set up and conducting the research sequences..
- feasibility of diffusion and perfusion magnetic resonance imaging (MRI) [ Time Frame: 1 year ]This is a technology assessment protocol for response to treatment. The study is designed to assess the utility of the technology using a limited number of participants. We will assess whether the MR parameters are predictive markers of early response.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01974804
|United States, New York|
|Memorial Sloan Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Kathryn Beal, MD||Memorial Sloan Kettering Cancer Center|